Personalis (NASDAQ:PSNL) updated its FY 2021 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of $-1.510-$-1.490 for the period, compared to the Thomson Reuters consensus estimate of $-1.550. The company issued revenue guidance of $85 million-$85 million, compared to the consensus revenue estimate of $85.01 million.Personalis also updated its Q4 2021 guidance to $-0.510-$-0.490 EPS.
Several research firms recently issued reports on PSNL. HC Wainwright reaffirmed a buy rating and set a $50.00 price target on shares of Personalis in a research note on Thursday, September 23rd. BTIG Research reaffirmed a buy rating and set a $29.00 price target on shares of Personalis in a research note on Friday, November 5th. Needham & Company LLC lowered shares of Personalis from a buy rating to a hold rating in a research note on Wednesday, November 3rd. Morgan Stanley downgraded Personalis from an overweight rating to an equal weight rating and decreased their price target for the stock from $32.00 to $25.00 in a research note on Friday, November 5th. Finally, Citigroup cut their price objective on Personalis from $37.00 to $30.00 and set a buy rating on the stock in a research note on Thursday, August 5th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of Hold and an average target price of $34.90.
PSNL traded up $0.56 on Thursday, hitting $14.51. 311,041 shares of the company’s stock were exchanged, compared to its average volume of 652,979. The firm has a market cap of $649.82 million, a PE ratio of -10.59 and a beta of 1.45. Personalis has a twelve month low of $13.40 and a twelve month high of $53.46. The stock has a fifty day moving average of $18.83 and a two-hundred day moving average of $20.74.
In other Personalis news, CFO Aaron Tachibana sold 3,152 shares of the firm’s stock in a transaction that occurred on Friday, September 17th. The shares were sold at an average price of $21.25, for a total value of $66,980.00. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO John Stephen West sold 100,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 12th. The shares were sold at an average price of $19.33, for a total transaction of $1,933,000.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 111,952 shares of company stock worth $2,174,574. 7.50% of the stock is owned by company insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. BNP Paribas Arbitrage SA increased its stake in shares of Personalis by 133.5% during the third quarter. BNP Paribas Arbitrage SA now owns 9,057 shares of the company’s stock valued at $174,000 after acquiring an additional 5,178 shares during the period. Invesco Ltd. increased its stake in shares of Personalis by 12.5% during the third quarter. Invesco Ltd. now owns 17,720 shares of the company’s stock valued at $340,000 after acquiring an additional 1,971 shares during the period. Wells Fargo & Company MN increased its stake in shares of Personalis by 97.4% during the second quarter. Wells Fargo & Company MN now owns 45,492 shares of the company’s stock valued at $1,152,000 after acquiring an additional 22,446 shares during the period. Finally, Bank of New York Mellon Corp increased its stake in shares of Personalis by 14.9% during the third quarter. Bank of New York Mellon Corp now owns 124,962 shares of the company’s stock valued at $2,404,000 after acquiring an additional 16,174 shares during the period. Institutional investors and hedge funds own 68.52% of the company’s stock.
Personalis Company Profile
Personalis, Inc engages in the provision of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in 2011 and is headquartered in Menlo Park, CA.
Featured Article: Dogs of the Dow
Receive News & Ratings for Personalis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Personalis and related companies with MarketBeat.com's FREE daily email newsletter.